Study identifier:D1441C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
The effect of Quetiapine on psychotic-like symptoms in borderline personality disordered patients: A Randomised Placebo-Controlled Trial
Borderline personality disorder
Phase 2
No
Quetiapine fumarate, Placebo
All
40
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Placebo Comparator: 1 Placebo | Drug: Placebo placebo Other Name: n/a |
Experimental: 2 Flexible doses of 200 mg/day to 600 mg/day quetiapine fumarate | Drug: Quetiapine fumarate flexible doses from 200 mg to 600 mg Other Name: Seroquel Other Name: 204,636 |